Figure 7
A schematic model of the HBV/BST-2 counteractivity.
BST-2 tethers HBV at the lumen of MVBs, restricting HBV particle formation and release after the fusion of MVBs with the plasma membrane. HBx co-localizes and potentially counteracts intracellular BST-2 and inactivates its antiviral function specifically in hepatocytes through an undefined mechanism.
